The Filing Desk

Alumis vs Celularity

Alumis ALMS · Celularity CELU · Pharmaceuticals

Celularity reported revenue of $26 million in fiscal 2025, about the same as Alumis' $24 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -230.9% at Celularity.

Side by side

AlumisCelularity
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$24M$26M
Revenue growth—−51.0%
Revenue growth a year, last 5 years—13.1%
Gross margin—24.4%
Operating margin−1,886.9%−230.9%
Net margin−1,011.8%−345.4%
Free cash flow−$370M—
Free cash flow margin−1,539.2%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count200.0%16.9%
Last close$4.33$0.47
P/E at the last close——
Insider trades, last 12 monthsbought $34.3 million, sold $1.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlumisCelularity
Operating margin
Percent of revenue
AlumisCelularity
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisCelularity

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and Celularity pages.